Justin M. Watts, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL Recorded on May 14, 2021 Terminology, available tests, the impact of epigenetics, and the significance of mutations. Understanding the role of genomics in cancer care can be complex. Tune in as Dr. Justin Watts from the Sylvester Comprehensive Cancer Center in Miami, breaks down cancer genomics, discusses the implications of treatment, outlines the various tests available, including their strengths and weaknesses, the importance of educating patients on the meaning of these tests, and the future of genomic testing in hematologic malignancies. Justin M. Watts, MD Associate Professor of Medicine Pap Corps Endowed Professorship in Leukemia Division of Hematology, Department of Medicine University of Miami, Sylvester Comprehensive Cancer Center Miami, FL

Peter Campbell, PharmD, BCOP, Columbia University Irving Medical Center, New York, NY Recorded on April 23, 2021 The interprofessional oncology team is comprised of many healthcare professionals, each playing an important role in contributing to a patient’s care. Join Dr. Peter Campbell, Clinical Pharmacy Manager from Columbia University Irving Medical Center, as he discusses the vital role of pharmacists on the multidisciplinary team. Dr. Campbell discusses challenges with access to treatment, cost of drugs, and adherence. He reviews many common and novel side effects patients experience, understanding drug-drug interactions, how to determine when to stop treatment, and how to navigate drug shortages. Join this interesting conversation to learn more about exciting drugs coming down the pipeline, how COVID-19 has impacted treatment, and so much more! Peter Campbell, PharmD, BCOP Clinical Pharmacy Manager Hematology/Oncology NewYork-Presbyterian Hospital Columbia University Irving Medical Center New York, NY

Edward A. Stadtmauer, MD, The University of Pennsylvania, Philadelphia, PA Recorded on February 23, 2021 In recognition of March being Myeloma Awareness Month, The Leukemia & Lymphoma Society is pleased to share this informative podcast episode on updates and advancements in multiple myeloma. Healthcare professionals are challenged to stay up-to-date on new and emerging treatments options, including updates in immunotherapy, and to incorporate these treatment approaches into decision making. Dr. Edward Stadtmauer, from The University of Pennsylvania, shares his insights into these topics, as well as discusses myeloma in underserved communities, treatment in the time of the COVID-19 pandemic, and exciting advances in multiple myeloma. Edward A. Stadtmauer, MD Section Chief of Hematologic Malignancies Roseman, Tarte, Harrow, and Shaffer Families’ President’s Distinguished Professor Hematology-Oncology Division Perelman Center for Advanced Medicine The University of Pennsylvania Philadelphia, PA

Michael Angarone, DO, FIDSA, Feinberg School of Medicine, Chicago, IL Recorded on February 25, 2021 There are so many questions cancer patients and their families have about the COVID-19 vaccine. What are the differences between the vaccines available? How do they work? Who should get vaccinated? Can one resume activities once vaccinated? This important podcast episodes aims to dispel myths surrounding the COVD-19 vaccine and reiterate its safety for oncology patients, their families, and healthcare professionals. Join our guest, Dr. Michael Angarone of Northwestern University, as he underscores the importance of this vaccine.    Michael Angarone, DO , FIDSA Associate Professor Department of Medicine Division of Infectious Disease Department of Medical Education Feinberg School of Medicine Chicago, IL

Sonali M. Smith, MD, FASCO, The University of Chicago, Chicago, IL Recorded on January 25, 2021 How do we start the conversation? How do we discuss patient expectation and the likelihood of relapse? What role does the timing of relapse play? In this episode, Dr. Sonali Smith, the Elwood V. Jensen Professor of Medicine at The University of Chicago, discusses expectations for disease control and for relapse, the mechanisms of resistance, exciting advances in the treatment of relapsed/refractory lymphoma, including new treatments, and so much more. Tune in to this important talk today! Sonali Smith, MD, FASCO Elwood V. Jensen Professor of Medicine Chief, Section of Hematology/Oncology Co-Leader, Cancer Service Line Co-Director, Lymphoma Program The University of Chicago Chicago, IL This podcast episode is supported by Epizyme.

Olatoyosi Odenike, MD and Wendy Stock, MD Recorded on January 15, 2021 Join Drs. Wendy Stock and Olatoyosi Odenike from The University of Chicago Medicine, in an important discussion on the progress in the treatment of acute myeloid leukemia, including important updates from the LLS Beat AML Master Trial. Drs. Stock and Odenike talk with Dr. Ken Miller about determining a treatment plan for each patient, the role genetics and epigenetics may play, what the ultimate goals of care are, including having difficult conversations with patients regarding treatment, and monitoring for measurable residual disease and maintenance therapy. Be a part of the conversation today! Olatoyosi Odenike, MDProfessor of MedicineDirector, Leukemia ProgramSection of Hematology/OncologyThe University of Chicago MedicineChicago, IL Wendy Stock, MDAnjuli Seth Nayak Professor of Leukemia ResearchThe University of Chicago MedicineChicago, IL

Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR Recorded on December 14, 2020 What is follicular lymphoma and how does it differ from other indolent lymphomas? Can this cancer be cured? Join Dr. Ken Miller as he speaks with Dr. Jeff Sharman, Director of Research at Willamette Valley Cancer Institute and Medical Director of Hematology Research for The US Oncology Network to discuss this disease. Dr. Sharman reviews the current treatment options as well as upcoming treatment approaches, including the latest from research presented at the 2020 American Society of Hematology (ASH) Annual Meeting. Jeff Sharman, MD Director of Research Willamette Valley Cancer Institute Medical Director of Hematology Research The US Oncology Network Eugene, OR This podcast episode is supported by Epizyme.

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA Recorded on November 19, 2020 Morphology was once the only means of classifying blood cancers especially CLL; flow cytometry, cytogenetics and immunohistochemistry all followed. With a revolution in understanding, there is now a growing list of molecular tests that provide even more precise diagnostic and prognostic tools in diagnosis and treatment decisions. In this episode, Dr. Ken Miller speaks with Dr. Jennifer Brown from the Dana-Farber Cancer Institute about cancer genomics, its current applications in diagnosis, prognosis, treatment decisions, risk of recurrence, and the future of genomics testing in hematologic malignancies. Tune in to this informative conversation today! Jennifer Brown, MD, PhD Director, CLL Center Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School Institute Physician Dana-Farber Cancer Institute Boston, MA This podcast episode is supported by Foundation Medicine, Inc.

Matthew B. Schabath, PhD, Moffitt Cancer Center, Tampa, FL Recorded on November 2, 2020 Individuals in the LGBTQI community face many barriers in accessing healthcare. In this episode, Dr. Matthew Schabath from the Moffitt Cancer Center addresses ways healthcare professionals can be more competent in supporting persons within this community. Dr. Schabath breaks down the terminology and stakeholders within this group to help make conversations comfortable and more productive with patients and their caregivers, discusses an overview of COLORS training and its importance, and describes how best to include caregivers and loved ones in patient care. Join this important conversation today! Matthew B. Schabath, PhD Associate Member in Cancer Epidemiology Moffitt Cancer Center Tampa, FL

Gail J. Roboz, MD, Weill Cornell Medical College, New York, NY Recorded on October 2, 2020 Minimal/measurable residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment. In this episode, Gail Roboz, MD, from Weill Cornell Medical College, provides an overview of MRD, including understanding its definition, explains the role advancements in technology have played in detection, and underscores the importance of understanding to what degree this detection can be helpful. Dr. Roboz provides strategies to communicate with patients about the impact of MRD on prognosis, treatment and outcomes and discusses the future of MRD testing in blood cancers. Tune in today! Gail J. Roboz, MD Director, Clinical and Translational Leukemia Programs Professor of Medicine Weill Cornell Medical College The New York Presbyterian Hospital New York, NY This podcast episode is supported by Amgen.